Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
Insulin is not the only hormone that regulates plasma glucose levels. Glucagon-like peptide 1 (GLP-1), produced in the small intestine, and amylin, produced by beta cells in the pancreas, also have glucose-lowering effects. Synthetic analogues of these hormones are now available for clinical use.
Hoogwerf
Byron J
BJ
Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland Clinic Foundation, OH 44195, USA. hoogweb@ccf.org
D000682:Amyloid / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide; D010455:Peptides / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*
D000682:Amyloid; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D010455:Peptides; D014688:Venoms; D000077270:Exenatide; C105254:pramlintide